Related Experiment Video
Updated: Jun 12, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
[HIV and hepatitis C co-infection]
M Vogel1, C Boesecke, J-C Wasmuth
1Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn.
Insights
HIV and Hepatitis C Virus (HCV) co-infection accelerates liver disease progression. Early HAART initiation and HCV treatment are recommended for co-infected patients to slow fibrosis and prevent complications.
Area of Science:
- Hepatology
- Infectious Diseases
- Immunology
Background:
- Chronic hepatitis C virus (HCV) infection is a major comorbidity in HIV-infected individuals, affecting one-third in Europe.
- HIV/HCV co-infection accelerates liver cirrhosis, decompensation, and hepatocellular carcinoma compared to HCV mono-infection, especially with severe immunodeficiency.
Purpose of the Study:
- To review the epidemiology and natural course of HCV in HIV co-infection.
- To summarize current guidelines for managing chronic hepatitis C in HIV co-infected patients.
Main Methods:
- Literature review of epidemiological data.
- Analysis of the natural history of HCV in the context of HIV.
- Synthesis of current clinical management guidelines.
Main Results:
- Immune reconstitution with HAART slows liver fibrosis progression in HIV/HCV co-infected individuals.
- HCV treatment with pegylated interferon and ribavirin can halt disease sequelae.
Conclusions:
- Early HAART initiation is advised for HCV co-infected patients.
- All HIV/HCV co-infected patients should be evaluated for HCV treatment eligibility.
Abstract:
Chronic hepatitis C virus (HCV) infection is currently one of the most clinically relevant co-morbidities in the HIV-infected population. Overall, one third of HIV-infected individuals in Europe are HCV co-infected. The progression of chronic HCV infection to liver cirrhosis with subsequent risk for liver decompensation and hepatocellular carcinoma is substantially accelerated in HIV/HCV co-infected compared to HCV mono-infected individuals, particularly with advanced levels of immunodeficiency. Indeed, immune reconstitution under HAART has been associated with slowing down fibrosis progression in HIV/HCV co-infected individuals. Therefore HAART initiation is recommended earlier in HCV co-infected patients. Moreover, the sequelae of chronic hepatitis C infection can be stopped by successful treatment with pegylated interferon and ribavirin combination therapy so that every HIV/HCV co-infected patient should be evaluated for possible HCV treatment. - In this review we summarize the current epidemiology, natural course of HCV in HIV co-infection and current guidelines for management of chronic hepatitis C infection in HIV co-infected patients.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Cytomegalovirus Disease
Retrovirus Life Cycles
Sexually Transmitted Infections
Herpes
